Skip to main content
. Author manuscript; available in PMC: 2022 Dec 1.
Published in final edited form as: Clin Cancer Res. 2022 Jun 1;28(11):2461–2473. doi: 10.1158/1078-0432.CCR-21-3207

Figure 4. Chemoimmunotherapy elicits pronounced immune-wide expression changes in resectable NSCLC.

Figure 4.

A) Violin plots for cellular signatures scores in patients with (% of viable tumor cells ≤10%, orange) and without pCR / MPR (>10% of viable tumor cells, blue). P-values were calculated based on the Mann Whitney test; black lines represent median values, and gray lines correspond to 95% confidence interval (CI). B) Heat map showing 223 DEGs (adjusted p<0.05) that are associated with percent viable tumor cells in early-stage NSCLCs treated with neoadjuvant chemoimmunotherapy. C) Radar plot highlighting differences between pre- (red) and post-treatment samples (blue) for the cellular signature scores. D) Heat map showing 128 DEGs between pre- and post-treatment samples (adjusted p<0.05). Columns denote samples and rows represent single genes and (red, relatively higher expression; blue, relatively lower expression). P-values were calculated using Wilcoxon matched-pairs signed rank test. pCR: pathologic complete response, MPR: major pathologic response.